Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
The use of synthetic cannabinoids in English prisons is currently considered a “law, order and control” problem, with associated regulation and penalties. There is a clear and problematic disconnect between prison administrators and users. Resources for education, training and work opportunities are missing.